Xalkori, the Pfizser Inc’s drug to treat lung cancer patients with specific gene mutation has been effective in shrinking tumors in even rarer form of the disease which resists treatment. The data was presented at a medical meeting on Saturday.
The study involved 50 non small cell lung cancer patients with a gene mutation of the ROS1 gene. Xalkori treatment led to noteworthy tumor shrinkage in 72% of the tumors. 36 patients showed significant reduction in the tumor size and the tumor growth was completely halted in 9 patients.